RxDoctor Payments Data

Allon Rafael, MD

Clinical Cardiac Electrophysiology · Los Gatos, CANPI 1851553671

Payments from drug & device makers

$16,065in general payments, 2019–2025

Across 317 payments — averaging $50.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Biotronik Inc.$4K
  • Abbott$3K
  • Biosense Webster, Inc.$2K
  • Boston Scientific$1K
  • GSK$203
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$2001%
  • Speaking & faculty fees$1,2007%
  • Travel & lodging$2,72617%
  • Food & beverage$11,75773%
  • Education$1821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,065 in reported general payments places this provider in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$378,155
Medicare patients
521
Services billed
1,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$242,827
XareltoRivaroxaban80$89,731
EntrestoSacubitril/Valsartan21$16,532
Colchicine91$6,648
SotalolSotalol Hcl191$2,998
Flecainide Acetate55$2,278
Matzim LaDiltiazem Hcl16$2,083
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$1,821
Diltiazem 24hr ErDiltiazem Hcl35$1,370
Propafenone Hcl ErPropafenone Hcl11$1,276
Diltiazem 24hr Er (La)Diltiazem Hcl14$972
Pantoprazole Sodium92$954
Metoprolol Succinate63$783
Amiodarone Hcl24$714
ClopidogrelClopidogrel Bisulfate32$427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$161$89,73180 claims
NovartisEntresto$25$16,53221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Los Gatos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →